• English
  • Sign In
  • Contact Us
×
Webinars » Therapeutic Recombinant Antibody Development with Next Generation Proprietary CHO Expression System

Therapeutic Recombinant Antibody Development with Next Generation Proprietary CHO Expression System

Antibodies are widely used in several applications of biomedical research and therapeutics. The increasing antibodies demand for higher quantity and quality in these areas, especially in cancer therapy, changing the production way of traditional hybridoma derived-antibody to recombinant antibody.

Recombinant antibody is generated in vitro using synthetic gene of interest into a host expression system – bacteria, yeast, insect or mammalian cell lines. The choice of the expression system affects the yield and functionality of the recombinant antibody. Chinese Hamster Ovary (CHO) cells remain the biopharmaceutical industry’s leading workhorse for many therapeutic protein productions.

In this webinar, you will learn:

  • Overview of recombinant therapeutic antibody
  • Host selection for recombinant antibody expression
  • Why CHO expression system is still the favorable workhorse for recombinant protein production

  • Speaker: Dr. Tan Hui Foon, Field Application Scientist, GenScript Asia Pacific
  • Date: 30th November 2021
  • Time: 2pm-3pm SGT





Related services:

  • CHO-HT (High Throughput) Service
  • cost-effective solution which also enables small scale (microgram) to kilogram level protein production based on the same expression system for the best consistency and minimal surprises during the downstream steps.